Literature DB >> 12047910

Food intake inhibition and reduction in body weight gain in lean and obese rodents treated with GW438014A, a potent and selective NPY-Y5 receptor antagonist.

A J Daniels1, M K Grizzle, R P Wiard, J E Matthews, D Heyer.   

Abstract

Numerous reports have implicated theY5 receptor as the 'feeding' receptor mediating the orexigenic action of neuropeptide Y (NPY). This notion is supported by the correlation between the in vitro functional and binding activities of different peptide agonists and their potent stimulation of food intake in rodents. We have discovered a series of small molecule heterocycles with high affinity, selectivity, and functional antagonism for Y5 receptors. Intraperitoneal (i.p.) administration of GW438014A into rodents, resulted in a potent reduction of NPY-induced and normal overnight food intake. Brain levels of GW438014A were detected well in excess of its binding IC(50) for up to 3 h post-dosing. Daily (i.p., BID, 10 mg/kg) administration of this compound to Zucker Fatty rats for a period of 4 days resulted in a marked decrease in the rate of weight gain and a reduction in fat mass. No effect on food intake was observed following oral administration of GW438014A (25-100 mg/kg), consistent with the poor oral bioavailability (<3%) and low brain levels observed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12047910     DOI: 10.1016/s0167-0115(02)00034-4

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  11 in total

1.  A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.

Authors:  Akane Ishihara; Akio Kanatani; Satoshi Mashiko; Takeshi Tanaka; Masayasu Hidaka; Akira Gomori; Hisashi Iwaasa; Naomi Murai; Shin-ichiro Egashira; Takashi Murai; Yuko Mitobe; Hiroko Matsushita; Osamu Okamoto; Nagaaki Sato; Makoto Jitsuoka; Takahiro Fukuroda; Tomoyuki Ohe; Xiaoming Guan; Douglas J MacNeil; Lex H T Van der Ploeg; Masaru Nishikibe; Yasuyuki Ishii; Masaki Ihara; Takehiro Fukami
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

Review 2.  Neuropeptide Y in normal eating and in genetic and dietary-induced obesity.

Authors:  B Beck
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

3.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

4.  Modulation of neuropeptide Y expression in adult mice does not affect feeding.

Authors:  Linda Ste Marie; Serge Luquet; Toby B Cole; Richard D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-08       Impact factor: 11.205

5.  Neuropeptide Y2 receptors are involved in enhanced neurogenic vasoconstriction in spontaneously hypertensive rats.

Authors:  Kathryn A Gradin; Carsten L Buus; Jia-Yi Li; Ole Frøbert; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

6.  Heterogeneity of the neuropeptide Y (NPY) contractile and relaxing receptors in horse penile small arteries.

Authors:  Dolores Prieto; Luis Rivera de Los Arcos; Pilar Martínez; Sara Benedito; Albino García-Sacristán; Medardo Hernández
Journal:  Br J Pharmacol       Date:  2004-11-22       Impact factor: 8.739

7.  Estradiol decreases the orexigenic effect of neuropeptide Y, but not agouti-related protein, in ovariectomized rats.

Authors:  Jessica Santollo; Lisa A Eckel
Journal:  Behav Brain Res       Date:  2008-03-25       Impact factor: 3.332

Review 8.  Neuropeptide Y: a physiological orexigen modulated by the feedback action of ghrelin and leptin.

Authors:  Satya P Kalra; Pushpa S Kalra
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.633

Review 9.  Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity.

Authors:  C K Boughton; K G Murphy
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 10.  Obesity pharmacotherapy: current perspectives and future directions.

Authors:  Monika Misra
Journal:  Curr Cardiol Rev       Date:  2013-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.